Previous 10 | Next 10 |
2023-07-13 10:09:11 ET Gainers: Applied DNA Sciences ( APDN ) +29% . 60 Degrees Pharmaceuticals ( SXTP ) +21% . Exicure ( XCUR ) +13% . Psychemedics ( PMD ) +11% . Plus Therapeutics ( PSTV ) +9% . Losers: First W...
2023-07-12 17:25:53 ET Psychemedics ( NASDAQ: PMD ) has announced that its board of directors has approved a transition plan for the Company’s President and CEO position. Effective August 17 th , current Chairman of the Board, President, and CEO, Ray Kuback...
Brian Hullinger Will Succeed Ray Kubacki as CEO Effective August 17, 2023 Mr. Hullinger Brings 30 Years of Leadership Experience and a Proven Track Record of Driving Growth ACTON, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s l...
2023-05-09 18:03:18 ET Psychemedics press release ( NASDAQ: PMD ): Q1 GAAP EPS of -$0.07. Revenue of $5.9M (-9.2% Y/Y). For further details see: Psychemedics GAAP EPS of -$0.07, revenue of $5.9M
ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to...
2023-03-21 17:27:41 ET Psychemedics press release ( NASDAQ: PMD ): Q4 GAAP EPS of -$0.12. Revenue of $5.7M (-11.5% Y/Y). For further details see: Psychemedics GAAP EPS of -$0.12, revenue of $5.7M
ACTON, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2022. The Company also announced a quar...
Psychemedics press release ( NASDAQ: PMD ): Q3 GAAP EPS of -$0.02. Revenue of $6.5M (-3.0% Y/Y). For further details see: Psychemedics GAAP EPS of -$0.02, revenue of $6.5M
Psychemedics ( NASDAQ: PMD ) declares $0.07/share quarterly dividend , in line with previous. Forward yield 4.45% Payable Dec. 16; for shareholders of record Dec. 2; ex-div Dec. 1. See PMD Dividend Scorecard, Yield Chart, & Dividend Growth. For fu...
ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2022. The Company also announced a cash quarterly divid...
News, Short Squeeze, Breakout and More Instantly...
Psychemedics Corporation Company Name:
PMD Stock Symbol:
NASDAQ Market:
Psychemedics Corporation Website:
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a...
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024. The Company’s revenue for the quarter ended March 31,...
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the nega...